Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

The neutrophil-recruiting chemokine GCP-2/CXCL6 is expressed in cystic fibrosis airways and retains its functional properties after binding to extracellular DNA.

Jovic S, Linge HM, Shikhagaie MM, Olin AI, Lannefors L, Erjefält JS, Mörgelin M, Egesten A.

Mucosal Immunol. 2016 Jan;9(1):112-23. doi: 10.1038/mi.2015.43. Epub 2015 May 20.

PMID:
25993443
2.

Positive expiratory pressure - Common clinical applications and physiological effects.

Fagevik Olsén M, Lannefors L, Westerdahl E.

Respir Med. 2015 Mar;109(3):297-307. doi: 10.1016/j.rmed.2014.11.003. Epub 2014 Nov 12. Review.

3.

European Cystic Fibrosis Society Standards of Care: Framework for the Cystic Fibrosis Centre.

Conway S, Balfour-Lynn IM, De Rijcke K, Drevinek P, Foweraker J, Havermans T, Heijerman H, Lannefors L, Lindblad A, Macek M, Madge S, Moran M, Morrison L, Morton A, Noordhoek J, Sands D, Vertommen A, Peckham D.

J Cyst Fibros. 2014 May;13 Suppl 1:S3-22. doi: 10.1016/j.jcf.2014.03.009. Review.

4.

Lung function in the aging Swedish cystic fibrosis population.

Dennersten U, Lannefors L, Höglund P, Hellberg K, Johansson H, Lagerkvist AL, Ortfelt M, Sahlberg M, Eriksson L.

Respir Med. 2009 Jul;103(7):1076-82. doi: 10.1016/j.rmed.2009.01.020. Epub 2009 Feb 23.

5.

Guidelines for the management of pregnancy in women with cystic fibrosis.

Edenborough FP, Borgo G, Knoop C, Lannefors L, Mackenzie WE, Madge S, Morton AM, Oxley HC, Touw DJ, Benham M, Johannesson M; European Cystic Fibrosis Society.

J Cyst Fibros. 2008 Jan;7 Suppl 1:S2-32. Epub 2007 Nov 19.

6.

[Adaptations of the European Respiratory Society guidelines by the Aerosol Therapy Group of the French Lung Society on the use of aerosol therapy through nebulization].

Boe J, Dennis JH, O'Driscoll BR, Bauer TT, Carone M, Dautzenberg B, Diot P, Heslop K, Lannefors L; Groupe Aérosolthérapie (GAT) de la Société de Pneumologie de Langue Française (SPLF).

Rev Mal Respir. 2004 Nov;21(5 Pt 1):1033-8. French. No abstract available.

PMID:
15622355
7.

Physiotherapy in infants and young children with cystic fibrosis: current practice and future developments.

Lannefors L, Button BM, McIlwaine M.

J R Soc Med. 2004;97 Suppl 44:8-25. Review. No abstract available.

8.

[Better routines in connection with nebulizer therapy are required. New European guidelines serve as a guidance in Swedish health care, too].

Lannefors L, Persson O, Löfdahl CG.

Lakartidningen. 2002 Oct 17;99(42):4176-80. Swedish. No abstract available.

PMID:
12448299
9.
10.

European Respiratory Society Guidelines on the use of nebulizers.

Boe J, Dennis JH, O'Driscoll BR, Bauer TT, Carone M, Dautzenberg B, Diot P, Heslop K, Lannefors L; European Respiratory Society Task Force on the use of nebulizers.

Eur Respir J. 2001 Jul;18(1):228-42. No abstract available.

11.

Identification of MUC5B, MUC5AC and small amounts of MUC2 mucins in cystic fibrosis airway secretions.

Davies JR, Svitacheva N, Lannefors L, Kornfält R, Carlstedt I.

Biochem J. 1999 Dec 1;344 Pt 2:321-30.

12.

Mild cystic fibrosis mutations in Southern Sweden with special reference to S549I and T338I.

Schaedel C, Andersson AM, Kristoffersson AC, Kornfält R, Lannefors L, Holmberg L.

Clin Genet. 1998 May;53(5):383-6.

PMID:
9660057

Supplemental Content

Loading ...
Support Center